维思通和氯氮平维持治疗精神分裂症的两年随访对照研究  

A follow-up study of the maintenance treatment on the Schizophrenia with clozapine and risperidone

作　　者：任显峰 白慧丽[1] 郑素娟[1] 马照红 

机构地区：[1]山东省济宁市复退军人精神病院,山东济宁272000

出　　处：《中国民康医学》2003年第12期711-712,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:比较维思通和氯氮平对精神分裂症维持治疗的疗效复发及副作用。方法:对出院后坚持使用维思通和氯氮平维持治疗的精神分裂症病人进行疗效评定,并随访2年。结果:维思通对精神分裂症阴性症状的改善和社会功能恢复好于氯氮平,且副作用较少。结论:维思通维持治疗精神分裂症长期疗效总体优于氯氮平。Objective:To approach the effect and relapse which is produced by clozapine and risperidone in the maintenance treatment on the schizophrenia. Methods: By making a two-year follow-up study on the schizophrenia patients who insist on taking clozapine and risperidone in the maintenance treatment after leaving hospital. Results: In the treatment of schizophrenia, risperidone works better than clozapine in restraining the negative symptoms and recovering the social function.and moreover, it leads less by-effects. Conclusion:Risperidone effects is better than clozapine in the maintenance treatment of schizophrenia.

关 键 词：维思通 氯氮平 治疗 精神分裂症 副作用 受体 剂量 

分 类 号：R749.3[医药卫生—神经病学与精神病学]